United Therapeutics (UTHR) FCF Margin (2009 - 2026)

United Therapeutics (UTHR) has 18 years of FCF Margin data on file, last reported at 46.54% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 209.0% year-over-year to 46.54%; the trailing twelve-month figure through Mar 2026 stood at 44.87% (up 766.0% YoY), and the FY2025 full-year result was 45.4%, up 784.0% from the prior year.
• FCF Margin retreated to 46.54% in Q1 2026, from 73.08% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 73.08% in Q4 2025 to a low of 6.49% in Q2 2023.
• A 5-year average of 41.82% and a median of 40.15% in 2024 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin sank 2506 bps in 2024 and soared 3850 bps in 2025, its largest moves.
• Tracing UTHR's FCF Margin over 5 years: stood at 25.94% in 2022, then gained by 5 bps to 27.18% in 2023, then advanced by 27 bps to 34.58% in 2024, then jumped by 111 bps to 73.08% in 2025, then sank by 36 bps to 46.54% in 2026.
• Business Quant data shows UTHR's FCF Margin at 46.54% in Q1 2026, 73.08% in Q4 2025, and 35.11% in Q3 2025.